Preventing GVHD after leukemia stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 3 study tests whether giving post-transplant cyclophosphamide can better prevent a dangerous immune complication called GVHD compared with the usual standard medicines. You may be eligible if you are in remission from acute leukemia and planning a fully matched related-donor stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute leukemia (AML or ALL) that is in complete remission (with or without blood count recovery).
- You are planning a fully matched related donor transplant using donated stem cells from peripheral blood (8/8 match).
- You are scheduled for a myeloablative conditioning regimen (a high-intensity chemo/before transplant plan).
- Your heart and lung and kidney and liver function meet specific lab/scan thresholds (including ejection fraction ≥50%, creatinine clearance >50, and lung tests ≥50%).
- You can sign consent and are well enough for transplant (Karnofsky/Lansky score 70 or higher), without active infection or active disease.
- You are not pregnant or breastfeeding, and you (and your partner if relevant) can follow strict birth-control rules for one year after transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Hear when a new Acute Lymphoblastic Leukemia (ALL) in Complete Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.